Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best AI stocks to buy according to hedge funds. Earlier on June 6, a significant advancement in drug discovery was announced with the ...

For example, with OpenPhenom-S/16, Recursion presents an unprecedented improvement in recalling known biological relationships from the StringDB database in the public JUMP-CP cpg0016 dataset.

The Utah-based pharmaceutical company has trained a large language model to enable scientists to tap into dozens of machine learning models at once, saving them time during drug development.

Shares of Recursion Pharmaceuticals (RXRX -1.09%) fell this week. The stock lost 24% as of market close on Friday. The move comes as the S&P 500 and Nasdaq Composite both slipped slightly ...

SALT LAKE CITY-- (BUSINESS WIRE)-- Recursion, a digital biology company industrializing drug discovery, today announced it has entered into a global licensing agreement with Takeda Pharmaceutical ...

Shares in biotech company Recursion Pharmaceuticals (RXRX -3.49%) surged by more than 12% by 11 a.m. ET today. The move is due to a de-risking event in its drug discovery pipeline. Taking full ...

Recursion Pharmaceuticals , a biotech firm which uses artificial intelligence to discover new drug candidates, has agreed to buy smaller rival Exscientia for $688 million in an all-stock deal ...

Recursion Pharmaceuticals (RXRX) shares soared 5.8% in the last trading session to close at $5.84. The move was backed by solid volume with far more shares changing hands than in a normal session ...